A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Acute Kidney Injury (AKI), an abrupt decrease in kidney function, affects 5-18 percent of all hospitalized adults and 20-74 percent of those admitted to an intensive care unit (ICU). Severe AKI that is persistent (lasting ≥ 3 days) can be associated with increased risk of chronic kidney diseases (CKD), mortality and other long-term adverse outcomes.1-4
Since severe AKI in hospitalized patients has the potential for serious adverse outcomes, clinicians are working hard to identify the risk factors and provide early intervention to help improve outcomes and reduce overall healthcare costs.
Baxter, a global leader in acute care, and bioMérieux, a global leader in in vitro diagnostics, joined forces with PAS, the research and analytics division of Premier Inc. Together, they delved into the Premier® Healthcare Database (PHD) to seek real-world evidence on the consequences of persistent severe AKI in hospitalized patients.
Underpinning PAS’s healthcare improvement work is the PHD, comprised of over 20 years of de-identified data from more than 1,030 hospitals spanning multiple therapeutic and quality improvement areas. Currently, the PHD contains data from more than one billion inpatient and hospital-based outpatient encounters.
Utilizing data from the PHD, this retrospective real-world cohort study aimed to compare clinical outcomes, length of stay (LOS) and costs during initial hospitalization and 30-day follow-up between hospitalized patients with persistent severe AKI (PS-AKI) and those with non-persistent AKI (NPS AKI), overall, and stratified by ICU use during initial hospitalization. The study time was between Jan. 1, 2017 and Dec. 31, 2019, with 30-day follow-up outcomes and 365-day lookback for baseline serum creatinine level (SCr) and comorbidities assessment.
Researchers found:
The results of this study demonstrated the importance and value of identifying patients at risk and of PS-AKI.
The PHD will continue to provide life sciences partners like Baxter and bioMérieux the opportunity to use real-world data to conduct evidence-based studies of clinical outcomes to improve the overall quality, safety and cost-effectiveness of care.
In addition to life sciences organizations, PAS partners with academia, government agencies, and healthcare insurers and providers, providing them with PHD data for analyses of drugs, devices, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes.
Learn more: Discover how the PHD is fueling research conducted by the PAS research team, the Centers for Disease Control, the National Institutes of Health and others.
References:
The insights you need to stay ahead in healthcare: Subscribe to Premier’s Power Rankings newsletter and get our experts’ original content delivered to your inbox once a month.